BIOMATERIALS SUPPLIER PROTECTION PROVIDED IN SENATE PRODUCT LIABILITY BILL; MEASURE LACKS "FDA DEFENSE" LANGUAGE, NON-ECONOMIC DAMAGES CAP
This article was originally published in The Gray Sheet
Executive SummaryBiomaterials liability reform is included in the product liability bill passed by the Senate on May 10 in a 61-37 vote. The Senate bill, which had to have several contentious provisions removed before it passed, now must be reconciled with the broader liability reform bill passed by the House on March 10.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.